Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005027 · ClinicalTrials.gov registry record · Phase 2
Rebeccamycin Analog in Treating Patients With Advanced Kidney Cancer
A Phase 2 study, sponsored by Barbara Ann Karmanos Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00005027: Completed Phase 2 study, sponsored by Barbara Ann Karmanos Cancer Institute.
NCT00005027 is a Phase 2 study that has completed, run by Barbara Ann Karmanos Cancer Institute. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00005027, a Phase 2 study, has completed, sponsored by Barbara Ann Karmanos Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of rebeccamycin analog in treating patients who have advanced kidney cancer.
Interventions
- DRUG becatecarin
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-06 |
| Est. Completion | 2005-03 |
| Phase | Phase 2 |
What the finished NCT00005027 record still lists
NCT00005027 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which becatecarin is the first listed.
NCT00005027 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00005027 about?
NCT00005027 is a clinical study titled "Rebeccamycin Analog in Treating Patients With Advanced Kidney Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of rebeccamycin analog in treating patients who have advanced kidney cancer.
What is the current status of trial NCT00005027?
This trial is currently completed. It is a Phase 2 study. The study started on 2000-06. Estimated completion is 2005-03.
What interventions are being tested in trial NCT00005027?
The interventions under investigation include: becatecarin (DRUG).
Who is sponsoring clinical trial NCT00005027?
This trial is sponsored by Barbara Ann Karmanos Cancer Institute, which has 139 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia